Symbiosis Pharmaceutical Services (Symbiosis) has successfully manufactured its first batch of 10,000 vials at its newly established facility in Stirling, UK. This milestone production, commissioned by a long-standing client, is pivotal in supporting the development of a cancer immunotherapy currently undergoing Phase III trials. The launch of this facility aligns with Symbiosis’ strategic expansion of its sterile manufacturing capacity, addressing the increasing global demand for essential medicines.
The FDA-inspected and MHRA-licensed facility enhances Symbiosis’ capability to assist clients throughout the entire product lifecycle, from clinical trials to commercial supply. By boosting production capacity and operational flexibility, the facility allows for larger batch sizes and supports additional programs, facilitating a smoother transition for clients approaching late-stage and commercial launches.
This achievement is a testament to Symbiosis’ growth trajectory since its inception in 2011, evolving from a small start-up to a reputable global partner with over 150 specialists. The facility, inaugurated by Scotland’s Deputy First Minister, Kate Forbes, exemplifies ongoing investments in quality systems and advanced manufacturing capabilities. Colin MacKay, CEO of Symbiosis, emphasized the significance of this first batch, underscoring the company’s commitment to delivering life-changing treatments and enhancing support for clients advancing critical therapies.
Start your 7-day trial and see what the database can do →
